Eradication of Aujeszky's disease virus from a Swedish pig herd using gI-/TK-vaccine

An attenuated glycoprotein I-negative (gI-)/thymidine kinase-negative (TK-) constructed vaccine was used to eradicate Aujeszky's disease virus from a large farrow-to-finish herd in Sweden. The herd had had problems every year for seven years and two attempts to eradicate the virus without vaccination had failed. At the start of the vaccination programme 86 per cent of the 396 breeding animals were seropositive to the virus. In spite of evidence of virus circulation in the fattening units, no fatteners were vaccinated. The breeding stock was vaccinated every four months and monitored serologically. Seropositive sows and boars were culled at an economic rate. During the programme, four breeding animals seroconverted to gI. Another seven animals which seroconverted to gI were suspected to have been infected shortly before the first test and vaccination. When all the seropositive breeding animals had been culled, the fattening units were sampled and no seropositive animals were found. The herd was declared gI-negative 39 months after the start of the programme. Monitoring of the herd for another four years, until all the vaccinated animals had been culled, showed that the herd remained free from Aujeszky's disease virus.

Duration of protective immunity against ovine haemonchosis following vaccination with the nematode gut membrane antigen H11

To establish for how long protective antibody levels may be maintained, lambs were vaccinated with the gut membrane antigen H11 and challenged with Haemonchus contortus 14, 84, 126 or 168 days later. Compared to controls, mean faecal egg counts of vaccinated lambs were reduced by 97 per cent, 99 per cent, 92 per cent and 86 per cent respectively. Total worm burdens at postmortem five weeks after infection were reduced by 87 per cent, 94 per cent, 92 per cent and 62 per cent respectively. In vaccinated lambs, antibody levels to H11 peaked at about 60 days after the first vaccination and were maintained for the duration of the experiment. There was evidence of secondary antibody responses to H11 following challenge.

Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep

Sheep were immunized with a protective recombinant antigen (45W) from the cestode parasite Taenia ovis using three different vaccine delivery systems, either alone or in different combinations. The DNA encoding 45W was cloned into the expression plasmid pcDNA 3 and an ovine adenovirus to create nucleic acid and recombinant viral vector vaccines, respectively. Sheep received two vaccinations with various combinations of these two delivery systems and/or purified recombinant 45W protein in a conventional vaccine formulation containing Quil A as adjuvant (protein/Quil A vaccine). Sheep receiving two inoculations of either the nucleic acid or the recombinant adenovirus alone, demonstrated only low levels of 45W-specific antibody. However, immunization with either nucleic acid or recombinant adenovirus primed animals to mount an enhanced immune response after a subsequent vaccination with the protein/ Quil A vaccine. The most striking result was that sheep initially immunized with the nucleic acid vaccine and boosted with the recombinant adenovirus, mounted IgG1 responses > 65 fold higher than those of sheep receiving either vaccine alone. The level of antibody in these sheep was commensurate with that observed in animals vaccinated twice with the protein/Quil A adjuvanted vaccine. In both cases, host-protection from experimental challenge infection with T. ovis was obtained.

Feline leukaemia virus: a review of immunity and vaccination

The availability feline leukaemia virus (FeLV) vaccines has added a new and important dimension to the control of this infectious agent. FeLV vaccination is a controversial issue, however, partly because of differences in the formulation between the current products, partly because of conflicting claims by vaccine manufactures and partly because experimental trials have shown that none of the vaccines provides 100 per cent protection against infection. This paper reviews the role of the immune response in determining the outcome following exposure to FeLV and describes the importance of FeLV subgroups. The five commercial FeLV vaccines currently available in the USA and Europe are described and the published literature on efficacy studies is summarised. However, these efficacy studies are often difficult to interpret for various reasons, including the small numbers of animals used; differences in challenge methods, vaccine strains and vaccine dose employed; and differences in postchallenge monitoring protocols.

Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4

The minor capsid protein L2 of bovine papillomavirus type 4 (BPV-4) is a very effective prophylactic vaccine which induces the production of virus neutralising antibodies and prevents virus-induced papillomatosis. The virus neutralising activity resides in the first 200 N-terminal amino acids of L2 (L2a). To further investigate the humoral immune response to L2, and the role it plays during infection and in prophylactic vaccination, the presentation of B-cell linear epitopes of L2a has been analysed in calves infected with the virus but not vaccinated, and in calves vaccinated with virus, L2a or E7. Several B-cell epitopes have been identified in L2a by the use of overlapping peptides; the epitopes varied in the different groups of animals, indicating that the epitopes presented by denatured L2 are not presented by the virus, and that therefore, although responsible for L2 vaccine-induced immunity, they may play little role in naturally acquired immunity.

Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus

OBJECTIVE

To determine what risk factors, other than genetic predisposition, contribute to the incidence of feline infectious peritonitis (FIP) in private breeding catteries and animal shelters.

DESIGN

Cats from 7 catteries and a shelter were observed monthly for 1 year. At each visit, cats were examined, fecal samples were collected for determination of feline coronavirus shedding, and blood samples were collected for determination of coronavirus antibody titers. Diagnostic tests were performed on all cats that died of FIP.

ANIMALS

275 purebred or random-bred cats that were kept by private breeder-owners in homes.

RESULTS

24 cats died of FIP during the study. Development of FIP was not associated with cattery, mean cat number, mean age, sex, cattery median coronavirus antibody titer, husbandry and quarantine practices, caging and breeding practices, or prevalence of concurrent diseases. However, risk factors for FIP included individual cat age individual cat coronavirus titer, overall frequency of fecal coronarvirus shedding, and the proportion of cats in the cattery that were chronic coronavirus shedders. Deaths from FIP were more frequent in fall and winter, and on the basis of analysis of cattery records, the number of deaths varied yearly. Epidemics (> 10% mortality rate) were reported at least once in 5 years in 4 catteries.

CLINICAL IMPLICATIONS

Elimination of FIP from a cattery is only possible by total elimination of endemic feline enteric coronavirus (FECV) infection. The most important procedure to reduce FECV from catteries is elimination of chronic FECV shedders.

Use of dot-immunobinding assay for visual detection of rinderpest antibodies in vaccinated cattle

A dot-immunobinding (DIB) assay was used to detect rinderpest antibodies in cattle vaccinated with Kabete 'O' strain vaccine, using purified rinderpest virus. Of 120 serum samples from vaccinated and non-vaccinated animals, rinderpest antibodies were detected in 80%, 88.4% and 91.6% of samples at 2, 3 and 4 weeks postvaccination respectively. All the serum samples from non-vaccinated animals were negative. The DIB results had a good correlation with those of the micro neutralisation test. The technique is simple, easy to perform and suitable for routine use in detecting rinderpest antibodies following vaccination.

Successful pseudorabies vaccination in maternally immune piglets using recombinant vaccinia virus vaccines

Three gilts were vaccinated with a NYVAC vaccinia recombinant expressing glycoprotein gD of pseudorabies virus (PRV) (NYVAC/gD). After farrowing, the piglets were allowed to nurse normally to obtain colostral immunity and then were divided into four groups, receiving NYVAC/gD, a NYVAC recombinant expressing glycoprotein gB of PRV (NYVAC/gB), an inactivated PRV vaccine (iPRV), or no vaccine. The piglets were vaccinated twice, three weeks apart beginning at approximately two weeks of age and later challenged with virulent PRV oronasally. Piglets that received NYVAC/gB or iPRV were the best protected based on lack of mortality, lower temperature responses, decreased weight loss and decreased viral shedding after challenge. These results indicate effective strategies for stimulating active immune response while still under the protection of maternal immunity.

Development and efficacy of a vaccine against Streptococcus iniae infection in farmed rainbow trout

Formalin killed bacteria were used as a vaccine against Streptococcus iniae infections in farmed rainbow trout. A single intraperitoneal injection of this vaccine in trout resulted in specific antibody production detectable for 6 months. Trout vaccinated at 50 g were protected under laboratory (experimental disease) and field conditions (natural disease) for at least 4 months against S. iniae infection. Passive transfer of S. iniae specific antibodies conferred protection. Under field conditions, mortality of non vaccinated trout exceeded 50%, whereas mortality of vaccinated trout did not reach 5%. In addition, vaccinated trout under field conditions gained 20% weight when compared with non vaccinated fish.

Early protection of puppies against canine parvovirus: a comparison of two vaccines

Client-owned puppies randomly were assigned to receive one of two commercially available polyvalent vaccines. The response to the parvovirus portion of each vaccine was evaluated by determining antibody titers by hemagglutination inhibition. Significant differences were found between titers produced by the vaccines. Puppies vaccinated with one of the products had a more desirable result as demonstrated by a protective antibody titer after the first vaccination (p of 0.005), a protective antibody titer at a younger age (p of 0.02), a protective antibody titer by 12 weeks of age (p of 0.001), and a protective antibody titer by 16 weeks of age (p of 0.05). Puppies vaccinated with this product also had significantly higher titers at each sampling after vaccination.

Use of Rhodococcus equi virulence-associated protein for immunization of foals against R equi pneumonia

OBJECTIVE

To evaluate use of the virulence-associated protein of Rhodococcus equi in immunizing foals against R equi pneumonia.

ANIMALS

Eight (experimental group) and 6 (controls) mares with their foals.

PROCEDURE

Virulence-associated protein extracted from R equi was used to prepare an acetone-precipitated. Triton X-extracted (APTX) antigen. After determination of the efficacy of passive immunization, in untreated foals or in foals given plasma from a horse vaccinated with APTX antigen or from a nonvaccinated horse, a field trial was done to evaluate the efficacy of vaccination of 8 mares, twice with APTX before parturition, and of their foals at ages 3 and 5 weeks; 6 mares and their foals served as unvaccinated controls. All 2-day-old foals were given plasma from local donor horses inoculated with a locally produced bacterin. Serum opsonizing activity produced by vaccination with APTX was determined. Passively immunized foals were challenge exposed with an aerosol of virulent R equi. Foals of the field trial were exposed to enzootic R equi infection.

RESULTS

Inoculation with APTX resulted in high IgG antibody liters with opsonizing activity. Passive immunization of foals with plasma from an immunized horse enhanced bacterial clearance from the lungs, compared with that in foals not given plasma or given plasma without APTX antibodies. Vaccination of mares and foals exposed to natural infection resulted in development of R equi pneumonia in 4 of 8 vaccinated foals, but in only 1 of 6 unvaccinated foals.

CONCLUSIONS

Vaccination with APTX antigen led to high-titer, opsonizing antibody. Plasma from a vaccinated horse appeared to enhance clearance of R equi from the lungs of foals. Paradoxically, vaccination of mares and their foals with APTX antigen did not protect foals and may have enhanced R equi pneumonia in the foals.

Infectious bronchitis: effect of viral doses and routes on specific lacrimal and serum antibody responses in chickens

An enzyme-linked immunosorbent assay was used to measure the effect of various infectious bronchitis virus (IBV) (strain H-120) vaccine doses and routes of immunization on specific lacrimal and serum antibody responses. The results of the first trial showed that the maximum dose, 10(6) median embryo infective doses (EID50s), delivered by the ocular route elicited both a systemic and a local antibody response in the vaccinated chickens. Lower doses of vaccinal virus, 10(4) (median dose) and 10(2) (minimum dose) EID50 delivered by the same route did not induce a detectable systemic antibody response. A significant increase of IBV-specific lacrimal IgA was elicited by both the maximum and the median vaccine doses. The low vaccine dose (10(2) EID50) did not induce a detectable increase of lacrimal IgA. In a second trial approximately the same vaccine dose was administered to different chicken groups by ocular instillation, drinking water, spray, and cloaca. The results showed that all routes of vaccination tested, including the cloacal route, resulted in an increase of specific serum antibodies. Higher IgG levels were detected throughout the experimental period after vaccination by the ocular route as compared with vaccination via the drinking water. All routes of vaccination tested resulted in an increase of specific IgA in lacrimal fluid. The vaccine application methods spray, ocular instillation, and drinking water induced similar lacrimal IgA responses.

Anti-fecundity immunity to Schistosoma japonicum induced in Chinese water buffaloes (Bos buffelus) after vaccination with recombinant 26 kDa glutathione-S-transferase (reSjc26GST)

We have shown previously that immunisation of mice and pigs with recombinant 26 kDa GST (reSjc26GST) induces a pronounced anti-fecundity effect after experimental infection with Chinese Schistosoma japonicum. We report here that anti-fecundity immunity can also be induced against reSjc26GST in Chinese water buffaloes (Bos buffelus), important reservoir hosts for S. japonicum in China. Anti-Sjc26GST antibodies were produced in immunised buffaloes and, following challenge with S. japonicum cercariae, a 22.3% reduction in worm numbers was evident in vaccinated when compared with control animals. The anti-fecundity effect was characterised by a significant decrease in faecal egg output and eggs deposited in host tissues with those in the liver and intestine being reduced by about 50%. In addition to the anti-fecundity effect, reSjc26GST reduced by nearly 40% the egg-hatching capacity of S. japonicum eggs into viable miracidia. In terms of vaccination strategy, these effects would combine to diminish pathology in animals immunised with reSjc26GST and reduce transmission of schistosomiasis japonica.

Glycoprotein gE blocking ELISAs to differentiate between Aujeszky's disease-vaccinated and infected animals

Three blocking ELISAs for the detection of antibodies against glycoprotein E (gE) of Aujeszky's disease virus (ADV) in sera (an indirect blocking ELISA (gE-iELISA), a direct blocking ELISA (gE-dELISA) and a two-site 'sandwich' blocking ELISA (gE-sELISA)) have been developed. The gE-ELISAs are based on monoclonal antibodies (mAbs) directed to gE and detect gE-specific antibodies in sera by blocking the binding of mAbs to one (in the gE-iELISA and the gE-dELISA) or two (in the gE-sELISA) epitopes of gE. From a panel of thirteen gE-specific mAbs, mAbs, their conjugates and the combination coating mAb/conjugate that optimally detect anti-gE antibodies in the assays were selected. Sera from uninfected unvaccinated swine or swine vaccinated against different swine viral disorders were negative by three gE-ELISAs, the blocking gB-ELISA, and VNT. Swine vaccinated with gE-negative vaccine were seropositive in the gB-ELISA and VNT but were seronegative by three gE-ELISAs. Infected unvaccinated swine, infected swine vaccinated with gE-negative vaccine, and swine vaccinated with gE-positive vaccine were detected as seropositive by three gE-ELISAs as well as in the gB-ELISA. The gE-dELISA and the gE-sELISA proved to be specific and the most sensitive and reliable assays to distinguish ADV-infected swine from those vaccinated with gE-negative vaccine. These two gE-ELISAs were at least as sensitive as the gB-ELISA for detecting ADV-specific antibodies.

Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection

OBJECTIVE

To compare the ability of 6 commercially available multicomponent canine vaccines to stimulate antibody production in pups with variable amounts of maternally derived canine parvovirus (CPV) antibody and to induce protective immunity against challenge exposure.

ANIMALS

Sixty-three 5- to 6-week-old Beagle pups with passively acquired CPV antibody titer between 1: 20 and 1:320.

PROCEDURE

9 pups were assigned to each of 6 vaccine groups and 1 control group. Eight pups in each group were inoculated with vaccine or saline solution twice, with 3 weeks between administrations. The ninth pup served as an uninoculated contact control. Serum samples were obtained weekly and tested for CPV antibody by hemagglutination-inhibition assay. All pups were challenge exposed with virulent CPV-2a and CPV-2b at 14 to 15 weeks of age.

RESULTS

3 of the vaccines failed to provide protective immunity against challenge exposure because all pups in these groups became infected and most died. A fourth vaccine protected against death, but not infection and disease. Two of the 6 vaccines induced an immune response that was protective against infection and disease.

CONCLUSION AND CLINICAL RELEVANCE

Substantial differences existed among commercial vaccines available in 1994 in their ability to immunize pups with maternally derived CPV antibody. These differences caused many vaccinated pups to be susceptible to CPV disease for variable periods because some vaccines failed to immunize. Importantly, all 4 of the vaccines that performed poorly have recently been replaced by more effective products so that the 6 vaccines now perform similarly.

Risks of spreading foot and mouth disease through milk and dairy products

A review of epidemics of foot and mouth disease (FMD) has highlighted the important role which raw (untreated) milk can play in the spread of the disease in a country which is normally free of FMD and whose cattle are not routinely vaccinated. The greatest hazard is likely to be in the early stages of an outbreak, before disease control measures have been implemented. The spread of FMD through milk can be prevented by the effective application of control measures combined with 'codes of practice' for the treatment of potentially infected milk. The author considers the probable mechanisms of transmission of FMD by milk and dairy products. These mechanisms are based on the quantities of virus excreted in milk, the survival of the virus under various management and manufacturing conditions and the minimum doses required to initiate infection in susceptible animals by different routes. The key points for consideration when making a risk assessment of the importation of milk and dairy products are also discussed.

Economic analysis of alternative AD control programmes

The threat imposed by its virulence brings a presumption that Aujeszky's disease (AD) must be controlled because potential losses are high. Viewed as an economic problem, the decision on whether and how to control AD hinges on comparing the costs of doing so with the benefits (in terms of reduced production losses) to be gained. Four strategies are considered: (a) doing nothing, (b) suppressing and maintaining the disease at low prevalence levels by vaccination, (c) suppressing to low levels and then eradicating by culling remaining positive animals and (d) eradicating in one step by means of a test-and-slaughter policy. The net economic merits of each strategy are examined using data derived from specific vaccination studies established in Germany and the Netherlands. A computer model is developed to estimate disease costs under different technical, epidemiological and economic assumptions, allowing the economically optimal strategies to be explored. In general no single strategy can be recommended as the 'best' for dealing with AD, since it depends on a host of factors relating to pig density, prevalence levels, production system, trade relations, etc. As usual, economic realities complicate the quest for operational simplicity in disease control. However, for the regions of high pig density studied the most economic AD control strategy is to lower herd prevalence by intensive vaccination before completing eradication by test-and-removal of remaining positive animals.

Inactivated vaccine for protection against duck virus enteritis

Immunogenicity of inactivated tissue-culture-derived duck enteritis virus (DEV) vaccines was evaluated in white Pekin and mallard ducks. DEV from a Lake Andes outbreak was propagated in chicken embryo fibroblast cells, inactivated with beta-propiolactone, and emulsified with Freund's adjuvant (FA), multiple-oil emulsion (MOE), or Squalane-pluronic L121 (L121). White Pekin and mallard ducklings were vaccinated at 2 or 3 wk of age, respectively. Challenge at 2 wk postvaccination with a virulent DEV isolated from a Long Island outbreak indicated that inactivated Lake Andes (ILA) vaccine mixed with any of the above adjuvants conferred protection, even with a single-dose inoculation. Antibody responses to vaccination, as determined by indirect enzyme-linked immunosorbent assay, showed that ILA virus with FA induced an early production of antibodies similar to that induced by commercially available modified live virus (MLV) vaccine. However, the mean anti-duck virus enteritis (DVE) IgG titers determined by multiple samplings during the first 35 days postvaccination showed titers from ILA virus with FA to be at least 10 times higher than those induced by MLV vaccine. The highest antibody titers were induced by ILA mixed with FA followed by ILA mixed with the MOE and L121. The results of this study indicated that inactivated vaccine is as efficacious as modified live vaccine in enhancing protection against virulent DEV in waterfowl.

Efficacy of eastern equine encephalitis immunization in whooping cranes

An epizootic of eastern equine encephalitis (EEE) at the Patuxent Wildlife Research Center (PWRC), Laurel, Maryland (USA), in 1989 provided an opportunity to determine if EEE immunization protected whooping cranes (Grus americana). Based on seroconversion of 31% of sympatric hatch-year sandhill cranes, Grus canadensis, and a previous 35% case fatality rate in whooping cranes, 17 (37%) of the 46 susceptible whooping cranes should have been exposed to virus and six should have died. As there were no deaths in these birds, the EEE vaccination program appeared to be efficacious in this whooping crane population.

Aujeszky's disease (pseudorabies) virus eradication campaign in The Netherlands

The Dutch Aujeszky's disease virus (ADV) eradication campaign is based on vaccination with glycoprotein E deleted vaccines. In the first stage of the programme, that was started in September 1993, the transmission of ADV must be reduced sharply. Subsequently, the remaining sources of virus need to be traced and eliminated. During the final stage, vaccination should be forbidden. This paper summarizes the observations made during a field study on the eradication of ADV by vaccination and reports the design and preliminary results of the first stage of the Dutch eradication campaign.

Computer simulation to support policy making in the control of pseudorabies

A further integration of international markets makes a coordinated policy against contagious animal infections increasingly important. In the future, stricter demands are to be expected concerning the control and eradication of such infections. To anticipate these demands, a computer simulation model is created in which scenarios can be evaluated with respect to epidemiological and economic effects of the infections and control strategies. In this paper, the simulation model is described for Pseudorabies in swine. In the model, the population of herds is subdivided into two main herd types: breeding and finishing. Each herd is in one of 24 states per herd type. The states are based on (1) the reproduction ratio R which is the number of secondary cases caused by one infectious herd, (2) the prevalence for each value of R and (3) the expected number of infectious animals in an infectious herd within each prevalence range and for each R. The different values of R are based on experiments and field data in which different vaccination strategies were used. The transition matrix with the probabilities of every transition from one state to another is calculated on a weekly base. With this matrix the distribution of herds over states from week to week is derived. To include a dynamic element in the transition probabilities, the number of newly infectious herds per week is a function of animal and other contacts, including aerial, material and personal contacts. Calculations show that the infection in the Dutch swine population will not disappear without vaccination. With a vaccination scheme in which sows are vaccinated 3 times per year and fattening pigs 1 time per cycle the infection will ultimately be eradicated, but 2 vaccinations per cycle for fattening pigs are needed to eradicate the infection within an acceptable timespan (i.e. 2 to 3 years). The latter strategy will become compulsory in the Netherlands from October 1st 1995.